Inotersen and Propafenone Hydrochloride

• Generic Name: inotersen
• Dosage Forms: n.a.
• Other Brand Names: Tegsedi

Inotersen works by decreasing a protein called transthyretin (TTR, made primarily in the liver). Hereditary transthyretin-mediated amyloidosis (hATTR) is a rare condition in which abnormal deposits of TTR protein build up in many parts of the body, interfering with normal function.

Inotersen is used to treat polyneuropathy (damage of multiple nerves throughout the body) in adults with hATTR. inotersen can help reduce symptoms such as pain, numbness, tingling, abnormal heartbeats, diarrhea, constipation, weakness, and problems with movement in your arms or legs.

Inotersen is available only from a certified pharmacy under a special program.

Inotersen may also be used for purposes not listed in this medication guide.

• Generic Name: propafenone
• Dosage Forms: n.a.
• Other Brand Names: Rythmol, Rythmol SR

Used (as conventional [immediate-release] tablets) to prolong the time to recurrence of symptomatic, disabling paroxysmal supraventricular tachycardia (PSVT) (e.g., AV nodal reentrant tachycardia or AV reentrant tachycardia [Wolff-Parkinson-White, WPW, syndrome]) and symptomatic, disabling paroxysmal atrial fibrillation/flutter (PAF) in patients without structural heart disease.

Used (as extended-release capsules) to prolong the time to recurrence of symptomatic PAF in patients without structural heart disease. Safety and efficacy of extended-release capsules not established in patients with exclusively PSVT or atrial flutter.

One of several drugs that may be used for ongoing management of patients with PSVT who do not have structural or ischemic heart disease; generally reserved for patients in whom other therapies (e.g., catheter ablation, β-adrenergic blocking agents, diltiazem, verapamil) are ineffective or contraindicated.

Comparably effective to quinidine, disopyramide, flecainide, procainamide, sotalol in preventing recurrences of PAF and maintaining sinus rhythm following successful cardioversion of atrial fibrillation.

Safety and efficacy not established in patients with chronic atrial fibrillation.

Has been used for pharmacologic cardioversion of atrial fibrillation or flutter.

May be used for ongoing management of other supraventricular tachycardias (SVTs) (e.g., focal atrial tachycardia, junctional tachycardia).

Because of risk of proarrhythmia, do not use in patients with structural heart disease or ischemic heart disease.

As conventional (immediate-release) tablets, suppresses and prevents recurrence of documented life-threatening ventricular arrhythmias (e.g., sustained VT, VF). (See Mortality under Cautions.)